Why Patient Anatomy Matters: How Needle Length Affects Injection Depth
In evaluating a suspected SIRVA case, one of the most common questions is:
Was the needle too long for the patient?
That sounds straightforward, but it is actually an anatomical question rather than a needle-length question alone.
A 1-inch needle is always 25.4 mm long. The patient beneath it is not always the same. Between the skin and the deeper shoulder structures are variable amounts of:
subcutaneous tissue
↓
deltoid muscle
↓
bursa, tendon, periosteum, bone, or other deeper structures
Whether a given needle produces an appropriate intramuscular injection therefore depends on how those tissue layers compare with the needle's actual penetration depth.
This is why patient anatomy matters.
It also explains why body weight or BMI alone cannot reliably reconstruct where the needle tip went in a particular SIRVA case.
Key Takeaways
Needle length must be interpreted relative to both skin-to-muscle depth and muscle-to-bone/deeper-structure depth.
Too short a needle may result in subcutaneous rather than intramuscular deposition; too much penetration can potentially reach the bursa, rotator cuff, nerve, or proximal humerus.
The SIRVA literature repeatedly identifies sex, age, weight, BMI, subcutaneous thickness, muscle mass, and injection technique as relevant variables in selecting needle length.
A low BMI is not required for SIRVA. Large clinical series include patients with normal, overweight, and obese BMIs, and one major review concluded that injection technique appears more important than BMI alone.
A correctly chosen surface landmark does not necessarily guarantee an appropriate depth. A published case describes SIRVA despite an apparently appropriate injection location and perpendicular approach, with the authors attributing the event to possible overpenetration relative to the patient's deltoid thickness.
For causation analysis, the relevant question is not simply “Was a 1-inch needle used?” but “Could the documented needle, at the reported site and depth, plausibly have traversed this patient's soft tissues and reached the implicated structure?”
The Needle Has to Reach Muscle—but Stop There
For an intramuscular vaccination, two undesirable outcomes sit on opposite sides of the target.
If penetration is too shallow, vaccine may be deposited primarily in subcutaneous tissue.
If penetration is too deep, the needle can potentially traverse the deltoid and enter structures beneath it.
The anatomical “safe zone” is therefore not simply the distance from skin to muscle.
It is the thickness of the available muscle compartment after the needle has passed through the overlying adipose tissue.
Conceptually:
Minimum necessary penetration = enough to pass through subcutaneous tissue and enter muscle.
But:
Maximum desirable penetration = less than the distance to the underlying structure that should not be entered.
That margin varies among patients.
Why Skin-to-Muscle Thickness Matters
Subcutaneous tissue thickness determines how far the needle must travel before it even reaches the deltoid.
This is why a longer needle may be needed in a patient with greater adipose thickness.
Chow and colleagues recommend that needle selection account for factors including age, sex, BMI, and subcutaneous thickness, while also emphasizing that an excessively long needle relative to body habitus can injure deeper structures.
The opposite problem is also clinically relevant. If a needle is too short to reliably enter muscle, the vaccine may be deposited superficially. The SIRVA literature focuses more heavily on overpenetration, but proper vaccine administration requires avoiding both errors.
Muscle Thickness May Matter Even More for SIRVA
Once the needle enters the deltoid, the next question is:
How much muscle lies between the needle tip and deeper structures?
This is the variable most relevant to overpenetration.
A patient can have enough subcutaneous tissue that he or she does not appear “thin,” yet still have a relatively thin deltoid at the injection site.
This was explicitly raised in the Miyano case report. The patient had a BMI of 26.5 kg/m² and was therefore not particularly thin. The vaccination was reportedly placed three fingerbreadths below the acromion with the needle perpendicular to the skin, features the authors considered appropriate. Nevertheless, they proposed that a 1-inch needle may have penetrated beyond the thickness of the deltoid into the subdeltoid space. They specifically emphasized the need to consider individual muscle size when selecting needle length.
That case makes an important point:
BMI does not tell us deltoid thickness.
BMI Is an Imperfect Surrogate for Shoulder Anatomy
It is tempting to reason that thin patients are at risk of overpenetration and heavier patients are not.
The SIRVA evidence does not support such a simple rule. Wiesel and Keeling reviewed the clinical literature and noted that early ultrasound work suggested a theoretical increased risk in lower-BMI patients because of a thinner tissue envelope. However, subsequent SIRVA series included patients across a wide BMI range. Atanasoff's patients had a mean BMI of 27.2, while the larger Hesse cohort had a median BMI of 25.1. The authors concluded that injection technique appears more closely related to SIRVA than BMI alone.
That distinction is particularly important in a causation analysis. An expert should be cautious about statements such as:
“The patient was overweight, so the needle could not have been too deep.”
or:
“The patient was thin, so overpenetration must have occurred.”
Neither conclusion follows from BMI alone.
Why Weight and BMI Can Mislead
Two patients with the same BMI can have very different shoulder anatomy.
One may have:
greater subcutaneous fat,
less deltoid muscle,
smaller overall skeletal dimensions,
while another may have:
less fat over the deltoid,
substantially greater muscle thickness,
larger bone structure.
Age can further alter muscle mass independently of body weight.
Sex-related differences in body composition can also influence the relative thickness of fat and muscle. Bass and Poland note that needle-length selection has traditionally considered sex, age, and weight, citing differences in deltoid muscle mass and fat-pad thickness.
The more precise concept is therefore local tissue thickness, not simply overall body size.
Skin-to-Muscle and Muscle-to-Bone Are Different Measurements
The study by Shankar and colleagues is important enough that it should be understood conceptually rather than cited merely as a needle-length paper.
They specifically investigated the influence of:
skin-to-muscle thickness
and
muscle-to-bone thickness
on needle penetration at the adult deltoid injection site. Those are two different anatomical thresholds.
The first determines whether the needle reaches the muscle.
The second helps determine whether it remains within muscle or passes too deeply.
This creates three possible outcomes:
Needle tip before muscle → underpenetration
Needle tip within muscle → intended intramuscular deposition
Needle tip beyond muscle → potential overpenetration
For SIRVA, the third category is most relevant.
Why a Standard 1-Inch Needle Can Produce Different Results
A 1-inch needle is approximately 25 mm long. The SIRVA literature repeatedly notes that the subdeltoid bursa can lie much closer to the skin in some individuals.
Bodor and Montalvo's ultrasound work, repeatedly cited by later authors, placed the skin-to-bursa depth at approximately 0.8–1.6 cm in their measurements. Chow therefore notes that overpenetration with a needle too long for the patient's body habitus can potentially involve bursae, rotator cuff tendons, neurovascular structures, or other deeper tissues.
A 25-mm needle is therefore not intrinsically “too long.” It becomes too long relative to the tissue depth along the particular trajectory.
MRI-Based Work Has Raised the Same Concern
Barnes and colleagues cited MRI work by Lippert examining deltoid tissue depth and potential overpenetration.
Using modeled needle lengths, they reported predicted overpenetration in:
11% with a 5/8-inch needle,
55% with a 7/8-inch needle, and
61% with a 1-inch needle
within that particular study population and methodology.
Those numbers should not be interpreted as the real-world probability of SIRVA from those needle lengths. They reflect anatomical modeling of penetration, not observed SIRVA incidence. That distinction is critical.
A needle extending beyond the desired muscle depth creates an anatomical opportunity for injury. It does not mean injury necessarily occurred.
Needle Length Is Not the Same as Actual Penetration
Another important limitation is that the physical length of a needle is not necessarily identical to the amount of needle inserted.
Relevant variables include:
whether the needle was inserted fully to the hub,
whether the skin and subcutaneous tissues were compressed,
whether the soft tissue was flattened or bunched,
injection angle,
and arm position.
This is why a medical record stating only:
“1-inch needle used”
provides limited information about actual tip location. It tells us the maximum available needle length, not necessarily the final depth reached.
Soft-Tissue Compression Can Increase Effective Depth
If the injector depresses or compresses the soft tissues during insertion, the distance between the skin surface and deeper structures may effectively decrease.
This issue was specifically raised in the Natanzi teres minor cases. Their measured skin-to-abnormality distances were approximately 2.1–2.2 cm, shorter than a 2.54-cm needle, and the authors noted that compression of soft tissue could permit still greater penetration.
This again illustrates why needle length should not be interpreted independently of technique.
Bunching vs Flattening Can Change the Result
The pediatric literature provides a particularly clear demonstration that technique can alter effective tissue depth.
In a case report discussing humeral osteomyelitis after intramuscular vaccination, the authors reviewed data indicating that use of a 1-inch needle with a flattening technique could produce substantial predicted overpenetration in smaller adolescents, while bunching the tissue dramatically reduced that risk.
Although pediatric injection anatomy should not be directly extrapolated to adults, the underlying principle is relevant:
The same needle in the same person can have a different relationship to bone depending on how the tissue is positioned during injection.
Age Matters Because Muscle Mass Changes
Older age frequently appears in SIRVA cohorts. Wiesel and Keeling note that large SIRVA series have predominantly involved middle-aged and older adults and discuss age-related differences in shoulder tissue and muscle mass as possible contributors.
Age is relevant anatomically because muscle mass may decline without a proportionate reduction in body weight. Thus, an older adult with a normal or elevated BMI can still have relatively limited deltoid thickness.
Again, this reinforces why BMI alone is a poor reconstruction of needle depth.
Sex May Influence Tissue Distribution
Several large SIRVA series contain substantially more women than men.
Wiesel and Keeling reported female proportions above 80% in two major datasets.
Bass and Poland discuss sex-related differences in muscle mass and deltoid fat-pad thickness as possible anatomical contributors and note that sex and weight have historically informed needle-length recommendations.
However, this association requires caution. Female predominance in SIRVA reports does not establish that smaller deltoid muscle mass is the reason. Reporting patterns, vaccine utilization, health-seeking behavior, occupational exposure, and other variables may contribute.
Thus:
sex may inform anatomical plausibility, but
sex is not evidence of causation.
Small Stature Can Matter Even When BMI Is High
The Yuen case provides a useful example of why height, weight, and BMI need to be interpreted together. The patient was an 84-year-old woman measuring only 119 cm in height and weighing 47 kg, yet her calculated BMI was 33.2.
After vaccination she developed marked synovitis and a massive joint effusion. Imaging also showed chronic near-complete supraspinatus and infraspinatus tearing with muscle atrophy. The authors proposed that her small stature and habitus made identification of the appropriate injection site difficult, allowing an injection that was both too high and too deep to enter the subdeltoid bursa; because of the preexisting full-thickness cuff defect, they hypothesized communication with the glenohumeral joint.
This is a particularly useful causation example because it demonstrates that:
a high BMI does not necessarily equal a thick protective deltoid envelope.
Preexisting Anatomy Can Change Where Vaccine Material Travels
Patient anatomy matters not only before the needle stops, but also after vaccine deposition.
The Yuen case is again instructive. A preexisting near-complete rotator cuff tear created communication between the bursal and glenohumeral compartments. The authors proposed that vaccine entering the bursal space could therefore gain access to the joint, producing severe synovitis and effusion.
Whether that precise pathway can be proven in retrospect is another question.
But it highlights a broader point:
the same misplaced injection could have different biological consequences in different shoulders because the underlying anatomy is different.
Correct Location Does Not Necessarily Mean Correct Depth
SIRVA is often discussed as an injection being “too high.” But the Miyano report demonstrates that an injection can apparently be placed at a conventionally accepted surface location and still potentially penetrate too deeply.The authors reported an entry point three fingerbreadths below the acromion and perpendicular needle orientation, yet proposed that a 25.4-mm needle exceeded the patient's deltoid thickness and entered the subdeltoid space.
Thus there are at least two independent questions:
Was the surface location appropriate? and
Was the penetration depth appropriate for that patient?
One does not answer the other.
Why This Matters for Causation
This is where anatomy becomes useful without being overinterpreted. Suppose a patient states that the injection was extremely high and immediate pain occurred.
That history may support a potential SIRVA mechanism. If the patient also has very limited soft-tissue depth in the region and a long needle was inserted fully, the anatomical plausibility becomes stronger.
If early imaging then shows focal bursal, tendon, or osseous abnormality along that trajectory, the pieces become more internally consistent. But anatomy still does not prove causation.
The analysis should distinguish:
Anatomical possibility: Could the needle have reached the structure?
Anatomical probability: Given the documented site, depth, technique, and patient anatomy, how likely is that trajectory?
Medical causation: Does the complete clinical evidence support vaccination as the cause of the patient's condition?
These are three different questions.
A Long Needle Does Not Automatically Establish SIRVA
A common medicolegal error would be:
“A 1-inch needle was used in a small patient, therefore the needle entered the bursa.”
That is too strong. To reach that conclusion, one would ideally need information about:
actual injection location,
needle insertion depth,
whether the needle was fully inserted,
local tissue thickness,
arm position,
tissue compression,
and subsequent objective findings.
Without those data, a 1-inch needle may make overpenetration possible, but it cannot prove that it occurred.
A “Normal” Needle Length Does Not Exclude SIRVA Either
The reverse reasoning is equally problematic. If a commonly recommended needle length was used, that does not establish that the needle remained within the deltoid.
Population recommendations are necessarily based on groups. Individual patients vary. Miyano's case illustrates exactly this issue: conventional location and a standard 1-inch needle did not eliminate the authors' concern that the deltoid itself was too thin for the actual penetration depth.
Patient Anatomy Can Support Mechanism Without Proving Injury
For an expert review, anatomy is most useful when it is treated as one component of a larger causal chain:
patient-specific tissue anatomy
needle length and insertion depth
reported injection site and angle
↓
plausible needle trajectory
↓
potential structure reached
↓
timing and pattern of symptoms
↓
objective imaging or examination findings
↓
consideration of alternative explanations.
The strength of causation increases when these elements converge.
It weakens when they do not.
The Clinical Literature Does Not Support a Single “SIRVA Body Type”
This also deserves emphasis. Batra and colleagues reported five occupational SIRVA cases in healthcare workers, all women and all within a normal BMI range, and discussed the possibility that slimmer builds and thinner deltoid/fat pads may increase overpenetration risk.
But other studies include many overweight and obese patients. Wiesel and Keeling therefore caution that while tissue mass plausibly affects penetration depth, SIRVA development appears more closely related to injection technique than BMI itself.
So there is no scientifically defensible profile such as:
“SIRVA occurs only in thin women.”
The literature clearly does not support that.
What About Very Large Patients?
Greater subcutaneous thickness creates the opposite technical challenge.
A short needle may fail to deposit vaccine within muscle.
Bass and Poland emphasize that a one-size-fits-all approach to adult deltoid needle length is problematic and that sex, age, and weight should be considered in needle selection.
This is important because safe vaccine administration requires balancing:
avoiding underpenetration, against
avoiding overpenetration.
A universal move toward shorter needles would not solve the problem.
It could create another one.
Recent Literature Has Moved Toward Individualized Needle Selection
The more recent literature in the SIRVA database reflects increasing interest in individual anatomy.
The 2025/2026 primary-care review by Pankiewicz and Hardy cites both:
Laohawiriyakamol et al.'s MRI study of appropriate intradeltoid needle penetration depth, and
Kearns et al.'s systematic review examining variables that should inform deltoid needle-length choice.
This shift is conceptually important. Rather than treating needle selection as a fixed rule, the literature increasingly recognizes the importance of the relationship between needle length and actual tissue depth.
What Can Be Determined Retrospectively?
In many SIRVA cases, the precise depth cannot be reconstructed.
Medical records may contain:
vaccine type,
arm,
date,
perhaps needle length,
but often do not document:
exact distance from the acromion,
depth inserted,
tissue compression,
needle angle,
patient positioning,
or deltoid thickness.
This means retrospective statements about the exact needle path should usually be expressed as probabilities or anatomical plausibility, not certainty.
If MRI or ultrasound was obtained soon after vaccination, however, focal abnormalities may provide additional information. For example, a lesion immediately beneath a reported injection site at a depth reachable by the documented needle provides more meaningful anatomical correlation than a nonspecific abnormality remote from the proposed trajectory.
The Best Causation Analysis Is Patient-Specific
Needle length becomes most informative when applied to an individual rather than discussed in the abstract.
A useful analysis asks:
How thick was the subcutaneous layer likely to be?
How thick was the deltoid at the reported injection site?
What structure lay immediately beneath it?
What needle was used?
How much of that needle was inserted?
Was the tissue compressed, flattened, or bunched?
What was the angle?
Was the injection high, central, or low?
Did symptoms begin immediately?
Does the subsequent pathology correspond anatomically?
That is much more meaningful than simply categorizing someone as “thin,” “normal BMI,” or “obese.”
The Bottom Line
Patient anatomy matters because needle length has meaning only in relation to the tissues the needle must traverse.
A vaccine needle must be long enough to pass through subcutaneous tissue and reach the deltoid, but not so deep, at that particular site and in that particular patient, that it exits the muscle into deeper shoulder structures.
The literature demonstrates substantial variability in:
subcutaneous thickness,
deltoid muscle thickness,
body habitus,
age-related muscle mass,
sex-related tissue distribution,
and the distance from skin to deeper structures.
It also demonstrates that SIRVA occurs across a broad range of BMIs. Therefore:
BMI or body weight alone should neither establish nor exclude an overpenetration mechanism.
For causation, the stronger question is:
Given this patient's anatomy, the reported injection site and technique, and the documented needle length and insertion depth, was it anatomically plausible for the needle to reach the structure implicated by the subsequent clinical findings?
If the answer is yes, that supports a proposed mechanism.
It still must be integrated with timing, objective pathology, prior shoulder status, and competing explanations before drawing a causation conclusion.
References
Cook IF, Williamson M, Pond D. Definition of needle length required for intramuscular deltoid injection in elderly adults: an ultrasonographic study. Vaccine. 2006;24(7):937-940.
Bodor M, Montalvo E. Vaccination-related shoulder dysfunction. Vaccine. 2007;25(4):585-587.
Cook IF. An evidence-based protocol for the prevention of upper arm injury related to vaccine administration (UAIRVA). Hum Vaccin. 2011;7(8):845-848.
Barnes MG, Ledford C, Hogan K. A “needling” problem: shoulder injury related to vaccine administration. J Am Board Fam Med. 2012;25(6):919-922.
Shankar N, Saxena D, Lokkur PP, Kumar NM, William NC, Vijaykumar N. Influence of skin-to-muscle and muscle-to-bone thickness on depth of needle penetration in adults at the deltoid intramuscular injection site. Med J Armed Forces India. 2014;70(4):338-343.
Cook IF. Subdeltoid/subacromial bursitis associated with influenza vaccination. Hum Vaccin Immunother. 2014;10(3):605-606.
Natanzi N, Hebroni F, Bodor M. Teres minor injury related to vaccine administration. Radiol Case Rep. 2020;15(5):552-555.
Wiesel BB, Keeling LE. Shoulder injury related to vaccine administration. J Am Acad Orthop Surg. 2021;29(17):732-739.
Yuen WLP, Loh SYJ, Wang DB. SIRVA (Shoulder Injury Related to Vaccine Administration) following mRNA COVID-19 vaccination: case discussion and literature review. Vaccine. 2022;40:2546-2550.
Bass JR, Poland GA. Shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccination. Vaccine. 2022;40:4964-4971.
Chow JCK, Koles SL, Bois AJ. Shoulder injury related to SARS-CoV-2 vaccine administration. CMAJ. 2022 Jan 17;194(2):E46-E49.
Cook IF. Minimizing shoulder injury related to vaccine administration. Hum Vaccin Immunother. 2022;18(1):e1938495.
Miyano Y, et al. Chronic shoulder injury related to vaccine administration following coronavirus disease 2019 vaccination: a case report. J Med Case Rep. 2023;17:456.
Laohawiriyakamol T, Boonsri P, Phutphithak K, Niyomkarn T, Klabklay P, Chuaychoosakoon C. Appropriate intradeltoid muscle needle penetration depth in vaccine administration: an MRI study in Thailand. Front Immunol. 2023;14:1302891.
Kearns C, Houghton C, Dickinson E, et al. What variables should inform needle length choice for deltoid intramuscular injection? A systematic review. BMJ Open. 2023;13:e063530.
Atanasoff S, Ryan T, Lightfoot R, Johann-Liang R. Shoulder injury related to vaccine administration (SIRVA). Vaccine. 2010;28(51):8049-8052.
Batra S, Page B. Shoulder Injury Related to Vaccine Administration: Case Series of an Emerging Occupational Health Concern. Workplace Health Saf. 2021 Feb;69(2):68-72.
Pankiewicz M, Hardy A. Shoulder Injury Related to Vaccine Administration: Implications in Primary Care. The Journal for Nurse Practitioners, 2025; 22.
Comments